Improving clinical trials through the Blockchain: Boehringer Ingelheim and IBM to cooperate in Canada for more data security

the Boehringer Ingelheim (Canada) and IBM Canada to test the possibilities of the Blockchain in clinical studies. The collaboration is the first of its kind and aims to increase the quality of research and patient safety.

Brigitte Bernhardt
15. February 2019BTC$3.591,78 -0.29% part Facebook Twitter LinkedIn xing mail

Boehringer Ingelheim is the largest research-based pharmaceutical companies in Germany. The canadian subsidiary company, has on 12. February 2019 in the framework of the HiMSS conference in Orlando, Florida, announced partnership with IBM Canada. The company promises higher data security and greater transparency in the implementation and evaluation of clinical studies.

The Ecosystem for clinical trials is very complex, because different stakeholders involved. This leads to a limited trust, lack of transparency and inefficient processes (...).

Dr. Uli Brödl, Vice President for medicine and regulatory at Boehringer Ingelheim (Canada) explained the current Situation in the press statement.

Clinical studies frequently

distorted The weaknesses of the clinical studies, lie approximately in the forgery-proof archiving of medical data and the data at any time insight. A major challenge is the merging of data from different sources. This can, however, only lead to a distorted representation of the results of the study; the lack of transparency facilitated the manipulation of individual studies.

Incomplete or incorrect studies do not represent a danger for the patient. The main cause for the susceptibility to errors is the lack of transparency. The numerous sources of error in medical studies are described in detail in this post on www.spektrum.de .

Blockchain to store as a solution for more transparency

The Blockchain technology allows data from research institutions, pharmaceutical companies and the Doctors is safe and encrypted. IBM Canada brings its Know-how in the Blockchain-technologies in the collaboration. As a result, the necessary transparency in the complex test project can be created, Boehringer Ingelheim, through its cooperation partners.

IBM is looking forward to the collaboration with Boehringer Ingelheim, to find out how the Blockchain technology can improve the quality of clinical studies,

Claude Guay, General Manager, IBM Services at IBM Canada said.

Read also: New from QuadrigaCX: loss of Private Keys only faked?

lighting The pilot project in Canada in addition, the potential of the Blockchain technology to reduce costs due to the partial automation of the very complex processes of clinical trials.

BTC-ECHO recently reported on another project in the health wise, for a block-chain solution. Bitfury announced at the HiMSS conference – his collaboration with two partner companies.

Blockchain and Fintech Jobs : looking for a new challenge? In our job Board your current job ads from the Blockchain and Fintech companies.